Surya Pharma properties worth Rs 185 crore attached by ED

Published On 2022-10-20 12:45 GMT   |   Update On 2022-10-20 12:45 GMT

The Directorate of Enforcement (ED) has attached properties worth Rs 185.1 crore belonging to Surya Pharmaceuticals Ltd in a money laundering case.

The attached properties include building, plant, and machinery, the ED said in a statement on Tuesday.

The enforcement agency has taken the action under the Prevention of Money Laundering Act (PMLA), 2002.

ED initiated an investigation under the provisions of PMLA, 2002 on the basis of 2 FIRs registered by CBI on the complaint of State Bank of India, Chandigarh, and Punjab and Sind Bank, Karnal against Surya Pharmaceuticals Ltd, its Managing Director Rajiv Goyal and others for defrauding the banks to the tune of Rs 828 crore.

For more details, check out the link given below:

Money Laundering Case: Surya Pharma Properties Worth Rs 185 Crore Attached By ED

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News